GLP-1, Birth Control, and Pregnancy: The Washout Rules

Key takeaways

• Wegovy's FDA label requires a 2-month washout before any attempt at conception because semaglutide has a long ~1-week half-life.
• Mounjaro and Zepbound (tirzepatide, a dual GIP/GLP-1 receptor agonist) carry a unique label warning that oral contraceptives may become less effective after injection.
• Animal reproductive studies for semaglutide and tirzepatide showed fetal harm at clinically relevant exposures, which is why all GLP-1s for weight loss are not recommended in pregnancy.
• No GLP-1 currently has adequate human pregnancy or lactation safety data, and all labels advise stopping the medication when pregnancy is recognized or planned.
• Patients using oral birth control with Mounjaro or Zepbound should switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose escalation.

Why GLP-1 Pregnancy Rules Get Glossed Over

Most GLP-1 patients hear about nausea, cost, and injection technique long before anyone explains the pregnancy and contraception requirements buried in the FDA label. That is a real problem, because the washout windows are measured in weeks to months — not days — and the contraception warning on tirzepatide is unique among modern weight-loss drugs. If you are of reproductive potential and your prescriber rushed past these sections, this guide reconstructs what the labels actually say and how to translate them into a planning timeline.

GLP1Zoom doesn't prescribe or sell medication — we compare and redirect to licensed providers. Everything below is grounded in the current FDA prescribing information for , , , and , plus published animal reproductive toxicology data. Pregnancy decisions belong with your prescriber, OB-GYN, and ideally a maternal-fetal medicine specialist if you have additional risk factors.

The Wegovy Washout: Why 2 Months Before Conception

The (semaglutide 2.4 mg) FDA label is explicit: discontinue the medication at least 2 months before a planned pregnancy. That number is not arbitrary. Semaglutide has an elimination half-life of approximately one week, which means the molecule takes roughly 5 to 7 weeks to clear to negligible levels after the last injection. A 2-month buffer gives that washout time plus a margin before the fetal organ-formation window begins.

Ozempic, which is the same molecule (semaglutide) approved for type 2 diabetes rather than weight loss, follows the same pharmacokinetic logic. While the label addresses pregnancy in the context of diabetes management, the underlying half-life and washout reasoning is identical. Patients switching between Ozempic and Wegovy for any reason should not assume the washout clock resets — semaglutide is semaglutide.

The reproductive-toxicity rationale comes from animal studies. In rats, rabbits, and cynomolgus monkeys, semaglutide exposure was associated with embryofetal mortality, structural abnormalities, and altered growth at clinically relevant exposures. There is no adequate, well-controlled human pregnancy data because pregnant women have been excluded from the pivotal STEP trials, so the FDA pregnancy section relies on animal data plus the precautionary half-life math.

Mounjaro and Zepbound: The Oral Contraceptive Warning

and — both tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly — carry a contraception warning that is genuinely unique in the class. The FDA label states that tirzepatide may reduce the efficacy of oral hormonal contraceptives because of delayed gastric emptying, which can blunt absorption of the contraceptive hormones. This delay is most pronounced after the first dose and after each dose escalation.

The labeled mitigation is concrete: patients using oral contraceptives should either switch to a non-oral contraceptive method (such as an IUD, implant, injection, patch, or vaginal ring) or add a barrier method (such as condoms) for 4 weeks after initiation and for 4 weeks after each dose increase. This is not a vague suggestion — it is specific label language that any prescriber writing tirzepatide should walk a patient through.

• Switch to non-oral contraception (IUD, implant, depot injection, patch, or ring) — these bypass gastric absorption entirely.
• Or add a barrier method (condoms) for 4 weeks after starting tirzepatide and 4 weeks after every dose escalation.
• Wegovy and Ozempic (semaglutide) do not carry this specific oral contraceptive warning on the label, though gastric emptying is also delayed.
• The warning applies even if you have used the same oral contraceptive successfully for years before starting tirzepatide.

Side-by-Side: Every GLP-1 Pregnancy Label

Below is a synthesis of what each major label actually says about pregnancy planning, washout, and contraception. The differences are subtle but matter for planning. Always confirm against the most current prescribing information, because labels are updated as new data emerges and as the FDA negotiates new language with manufacturers.

• Wegovy (semaglutide 2.4 mg): Discontinue at least 2 months before planned pregnancy. Not recommended in pregnancy. No specific oral contraceptive warning.
• Ozempic (semaglutide for T2D): Same 2-month washout logic based on half-life. Discontinue when pregnancy is recognized. No specific oral contraceptive warning.
• Mounjaro (tirzepatide for T2D): Discontinue when pregnancy is recognized. Oral contraceptive efficacy may be reduced — switch method or add barrier for 4 weeks after start and each escalation.
• Zepbound (tirzepatide for weight loss and moderate-to-severe obstructive sleep apnea in adults with obesity, approved Dec 2024): Same contraception warning as Mounjaro; discontinue when pregnancy is recognized.
• Saxenda (liraglutide 3 mg, daily): Half-life is much shorter (~13 hours), so washout is shorter — but pregnancy is still not recommended; discontinue when recognized.
• Compounded semaglutide and tirzepatide: NOT FDA-approved as finished products. No standardized label exists; the underlying molecules carry the same theoretical pregnancy concerns, but compounded formulations have no independent reproductive safety review.

Animal Reproductive Toxicology: What the Trials Actually Showed

Because pregnant patients have been excluded from every pivotal trial (STEP for semaglutide, SURMOUNT for tirzepatide, SCALE for liraglutide), the FDA pregnancy sections rely heavily on animal reproductive studies. For semaglutide, studies in rats showed reduced fetal growth and skeletal abnormalities at exposures roughly equivalent to or below the maximum human dose. Rabbit and cynomolgus monkey studies showed similar embryofetal mortality and structural findings.

For tirzepatide, animal studies in rats and rabbits demonstrated decreased fetal weight and skeletal variations at maternally toxic doses. The mechanism is not fully understood, but the consistency across species — combined with the absence of human safety data — is why every GLP-1 and GIP/GLP-1 weight-loss label classifies pregnancy as a setting where the medication should not be used unless the potential benefit clearly justifies the potential risk to the fetus. In practice, for weight loss alone, that threshold is essentially never met.

The Breastfeeding Gap

Breastfeeding is the second major data gap. None of the GLP-1 weight-loss labels have adequate human lactation data. For semaglutide, the molecule was detected in the milk of lactating rats, but it is unknown whether semaglutide or tirzepatide transfer into human milk, what the local gastrointestinal effects on a breastfed infant would be, or what the longer-term implications might be. Because of this uncertainty, the labels advise that the developmental and health benefits of breastfeeding should be considered alongside the mother's clinical need for the drug and any potential adverse effects on the breastfed child.

Emerging evidence from small observational case series suggests very limited transfer of large peptide drugs into milk in general, but this is not the same as a well-controlled safety study. Anyone considering breastfeeding while on a GLP-1 should have that conversation with both their prescriber and a pediatrician who is comfortable discussing off-label drug-in-lactation decisions.

Building a Realistic Pre-Conception Timeline

If you are on a GLP-1 and planning pregnancy, the planning horizon is longer than most people expect. Weight regain after stopping is real — STEP-4 showed that patients who stopped semaglutide 2.4 mg regained a substantial portion of lost weight over the year that followed — so a pre-conception plan should also account for how weight changes might affect fertility, ovulation, and obstetric risk. This is a conversation for your prescriber and OB-GYN together, not a unilateral decision.

1. Talk to your prescriber as soon as pregnancy is on the horizon — not after you start trying.
2. For semaglutide (Wegovy or Ozempic): stop the medication and count 2 months before active conception attempts.
3. For tirzepatide (Mounjaro or Zepbound): follow the prescriber's washout guidance; the label calls for discontinuation when pregnancy is planned, and tirzepatide's half-life of roughly 5 days suggests a multi-week clearance.
4. Coordinate with your OB-GYN about prenatal vitamins, folic acid, and any metabolic comorbidities (insulin resistance, PCOS, type 2 diabetes) that need their own management plan during the GLP-1-free window.
5. Plan for possible weight regain during the washout period and discuss whether non-pharmacologic strategies or — if medically appropriate — a switch to a pregnancy-compatible diabetes medication (such as insulin or metformin in selected cases, per your prescriber) might bridge the gap.

If You Get Pregnant Unexpectedly on a GLP-1

Unintended pregnancy on a GLP-1 is increasingly common, partly because rapid weight loss can restore ovulation in patients with PCOS or obesity-related anovulation who assumed they were sub-fertile. If this happens, the first step is to stop the medication and contact your prescriber and OB-GYN promptly. Do not panic — the limited human pregnancy registry data published to date has not signaled a dramatic increase in major malformations, but the datasets are small and the FDA has not changed its precautionary stance.

Your OB-GYN will likely recommend standard early-pregnancy care: confirmation, dating ultrasound, baseline labs, and counseling on what is known and unknown about your specific exposure window. Some academic centers now have GLP-1 pregnancy registries, and your provider may discuss whether enrolling could contribute to the field's understanding. This is not a substitute for clinical care — it is an additional option some patients value.

What This Means for Affiliate Telehealth Patients

Many GLP-1 prescriptions today come through asynchronous telehealth platforms that may not surface contraception and pregnancy planning questions as thoroughly as an in-person visit would. If you obtained your medication through a telehealth provider and the intake form did not ask about reproductive plans, contraception method, or current pregnancy, that is a gap worth closing — either by messaging the platform's clinical team or by booking a synchronous visit with your primary care provider or OB-GYN.

For patients on compounded semaglutide or tirzepatide: these are NOT FDA-approved as finished products, which means there is no manufacturer-reviewed label that specifically addresses contraception or pregnancy for the compounded version. The underlying molecule's reproductive concerns still apply, but the compounded supply chain adds an extra layer of uncertainty — and most state-licensed pharmacies will defer to the underlying molecule's prescribing information when counseling. Always tell every clinician who treats you, including your OB-GYN, which exact product you are on.

Frequently asked questions

How long should I be off Wegovy before trying to get pregnant?

The Wegovy FDA label specifies discontinuation at least 2 months before a planned pregnancy. This buffer reflects semaglutide's approximately 1-week half-life, which means the drug takes 5 to 7 weeks to clear, plus an additional margin before fetal organ formation. Confirm timing with your prescriber and OB-GYN, since individual factors may warrant a longer washout.

Does Mounjaro really make birth control pills less effective?

Yes — the Mounjaro and Zepbound labels specifically warn that tirzepatide (a dual GIP/GLP-1 receptor agonist) may reduce oral contraceptive efficacy because of delayed gastric emptying. The labeled mitigation is to switch to a non-oral method like an IUD, implant, injection, patch, or ring, or to add a barrier method such as condoms for 4 weeks after starting and 4 weeks after each dose increase.

Is Ozempic safe during pregnancy?

Ozempic is not recommended during pregnancy. The active ingredient semaglutide showed embryofetal mortality, structural abnormalities, and altered growth in rat, rabbit, and cynomolgus monkey reproductive studies at clinically relevant exposures. There is no adequate, well-controlled human pregnancy data, so the FDA label advises discontinuation when pregnancy is recognized and planning conception only after appropriate washout.

Can I breastfeed while taking a GLP-1?

There is no adequate human lactation data for any GLP-1 weight-loss medication. Semaglutide was detected in the milk of lactating rats, but human milk transfer for both semaglutide and tirzepatide is unknown, as are the effects on a breastfed infant. The FDA labels advise weighing breastfeeding benefits against the mother's clinical need for the drug, and any decision should involve both a prescriber and a pediatrician.

What if I find out I'm pregnant while on Wegovy or Zepbound?

Stop the medication and contact your prescriber and OB-GYN promptly. Limited human pregnancy registry data published to date has not signaled a dramatic increase in major malformations, but datasets remain small and the FDA's precautionary stance has not changed. Your OB-GYN will guide standard early-pregnancy workup and may discuss enrollment in a pregnancy registry to help build the evidence base.

Do compounded GLP-1s follow the same pregnancy rules?

Compounded semaglutide and tirzepatide are NOT FDA-approved as finished products, so they do not carry a manufacturer-reviewed pregnancy label of their own. The underlying molecules' reproductive concerns still apply, but the compounded supply chain adds an extra layer of uncertainty. Disclose every product you are taking — including the compounding pharmacy and concentration — to every clinician involved in your reproductive care.

Why is there a contraception warning on Mounjaro but not on Wegovy?

Both delay gastric emptying, but the clinical pharmacology studies submitted for tirzepatide specifically demonstrated reduced absorption of an oral contraceptive after a tirzepatide dose. Similar dedicated studies were not part of the semaglutide submission package to the same degree, so the Wegovy and Ozempic labels do not carry that specific warning. Some clinicians still recommend extra contraceptive caution on any GLP-1 given the shared mechanism.

How long should I be off Mounjaro or Zepbound before pregnancy?

The tirzepatide labels call for discontinuation when pregnancy is planned but do not specify a 2-month figure the way Wegovy does. Tirzepatide's half-life is approximately 5 days, which suggests a multi-week clearance period. Discuss a specific washout window with your prescriber; many clinicians apply a conservative 4-to-8-week buffer by analogy to the semaglutide guidance until more tirzepatide-specific data emerges.